MedTrace Logo

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

NCT01082120 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2010-07-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether administration of AZD1656 will affect the pharmacokinetics of Pioglitazone and vice versa in patients with Type 2 Diabetes Mellitus.

Conditions

Interventions

DRUG

AZD1656

Tablets orally, twice daily for 10 days

DRUG

Pioglitazone

Tablet oral single dose for 10 days

Sponsors & Collaborators

Principal Investigators

  • Stanko Skrtic · AstraZeneca

  • Elaine Watkins, DO · Profil Institute for Clinical Research, Inc.

  • Mirjana Kujacic · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01082120 on ClinicalTrials.gov